COMMONS

Impact of EU regulation on UK life sciences examined

16 March 2016

The Science and Technology Committee examines the impact of EU regulation on the UK life sciences. Issues include the extent to which EU policies and policy-making constrain research and hinder or promote business competitiveness.

Witnesses

Tuesday 22 March 2016, Thatcher Room, Portcullis House

At 2.15pm

  • Stuart Pritchard, EU Affairs Manager, Wellcome Trust
  • Dr Keith Ison OBE, representing the Shelford Group
  • Professor Berne Ferry, representing the Shelford Group

At 3.00pm

  • Dr Jacqueline Barry, Director of Regulatory Affairs, Cell and Gene Therapy Catapult
  • Paul Browning, Head of Regulatory Affairs, Brightwake Ltd
  • Darren Budd, Commercial Director - UK and Ireland, BASF
  • Steve Bates, Chief Executive Officer, BioIndustry Association

At 3.45pm

  • Professor Roger Lemon FMedSci, Sobell Chair of Neurophysiology at University College London and Fellow of the Academy of Medical Sciences
  • Sir John Skehel FMedSci FRS, Vice-President and Biological Secretary, The Royal Society

Further Information

Image: iStockphoto

Share this page